Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study

被引:622
作者
Young, EW
Albert, JM
Satayathum, S
Goodkin, DA
Pisoni, RL
Akiba, T
Akizawa, T
Kurokawa, K
Bommer, J
Piera, L
Port, FK
机构
[1] URREA, Ann Arbor, MI 48103 USA
[2] Univ Michigan, Div Nephrol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA
[4] Hosp Gen Valle Hebron, Serv Nephrol, Barcelona, Spain
[5] Heidelberg Univ, Heidelberg, Germany
[6] Tokai Univ, Inst Med Sci, Kanagawa 2591100, Japan
[7] Wakayama Med Univ, Ctr Blood Purificat Therap, Wakayama, Japan
[8] Tokyo Womens Med Univ, Dept Blood Purificat & Internal Med, Tokyo, Japan
[9] ICOS Corp, Bothell, WA USA
关键词
mineral metabolism; vitamin D; phosphorus binders; calcium-phosphorus product; parathyroid hormone; DOPPS;
D O I
10.1111/j.1523-1755.2005.00185.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Altered mineral metabolism contributes to bone disease, cardiovascular disease, and other clinical problems in patients with end-stage renal disease. Methods. This study describes the recent status, significant predictors, and potential consequences of abnormal mineral metabolism in representative groups of hemodialysis facilities (N = 307) and patients (N = 17,236) participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS) in the United States, Europe, and Japan from 1996 to 2001. Results. Many patients fell out of the recommended guideline range for serum concentrations of phosphorus (8% of patients below lower target range, 52% of patients above upper target range), albumin-corrected calcium (9% below, 50% above), calcium-phosphorus product (44% above), and intact PTH (51% below, 27% above). All-cause mortality was significantly and independently associated with serum concentrations of phosphorus (RR 1.04 per 1 mg/dL, P = 0.0003), calcium (RR 1.10 per 1 mg/dL, P < 0.0001), calcium-phosphorus product (RR 1.02 per 5 mg(2)/dL(2), p = 0.0001), PTH (1.01 per 100 pg/dL, P = 0.04), and dialysate calcium (RR 1.13 per 1 mEq/L, P = 0.01). Cardiovascular mortality was significantly associated with the serum concentrations of phosphorus (RR 1.09, P < 0.0001) calcium (RR 1.14, P < 0.0001), calcium-phosphorus produc; (RR 1.05, P < 0.0001), and PTH (RR 1.02, P = 0.03). The adjusted rate of parathyroidectomy varied 4-fold across the DOPPS countries, and was significantly associated with baseline concentrations of phosphorus (RR 1.17, P < 0.0001), calcium (RR 1.58, P < 0.0001), calcium-phosphorus product (RR 1.11, P < 0.0001), PTH (RR 1.07, P < 0.0001), and dialysate calcium concentration (RR 0.57, P = 0.03). Overall, 52% of patients received some form of vitamin D therapy, with parenteral forms almost exclusively restricted to the United States. Vitamin D was potentially underused in up to 34% of patients with high PTH, and overused in up to 46% of patients with low PTH. Phosphorus binders (mostly calcium salts during the study period) were used by 81% of patients, with potential overuse in up to 77% patients with low serum phosphorus concentration, and potential underused in up to 18% of patients with a high serum phosphorus concentration. Conclusion. This study expands our understanding of the relationship between altered mineral metabolism and outcomes and identifies several potential opportunities for improved practice in this area.
引用
收藏
页码:1179 / 1187
页数:9
相关论文
共 17 条
[1]   Risk factors for vertebral fractures in renal osteodystrophy [J].
Atsumi, K ;
Kushida, K ;
Yamazaki, K ;
Shimizu, S ;
Ohmura, A ;
Inoue, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) :287-293
[2]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[3]   Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Raggi, P .
KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252
[4]   Hypocalcemia, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Hu, LQ ;
ODea, R ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (05) :386-393
[5]  
Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
[6]   Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The dialysis outcomes and practice patterns study (DOPPS) [J].
Goodkin, DA ;
Bragg-Gresham, JL ;
Koenig, KG ;
Wolfe, RA ;
Akiba, T ;
Andreucci, VE ;
Saito, A ;
Rayner, HC ;
Kurokawa, K ;
Port, FK ;
Held, PJ ;
Young, EW .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (12) :3270-3277
[7]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483
[8]  
Gupta A, 2000, J AM SOC NEPHROL, V11, P330, DOI 10.1681/ASN.V112330
[9]   Are we mismanaging calcium and phosphate metabolism in renal failure? [J].
Hsu, CH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (04) :641-649
[10]   European best practice guidelines for haemodialysis (part 1) Introduction [J].
Kessler, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :2-2